AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01378325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Prophylactic variable rate of phenylephrine infusion started at 0.75 µg/kg/min vs saline
Study NCT01378325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Prophylactic variable rate of saline infusion where we adjusted the pump at a starting rate of 0.75 µg/kg/min, equivalent to 0.0075 mL/kg/min of saline
Study NCT00311896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02578784 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angioplasty with drug-coated balloon
Description: Angioplasty with drug-coated balloon Elutax (Aachen Resonance, Germany)
Study NCT02578784 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Angioplasty with plain old balloon
Description: Angioplasty with plain old balloon Sterling (BostonScientific, Switzerland)
Study NCT03790657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: practice of a complex walking task
Description: walking over obstacles
Study NCT03790657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dosage A: transcranial direct current stimulation (tDCS)
Description: mild electrical stimulation delivered to the frontal region of the brain
Study NCT03790657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dosage B: transcranial direct current stimulation (tDCS)
Description: mild electrical stimulation delivered to the frontal region of the brain
Study NCT01968642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Study NCT00980395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 IV Day 1. Repeat every 28 days for a maximum of 6 cycles.
Study NCT00980395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: 1.3 mg/m2 IV Days 1 and 4. Repeat every 28 days for a maximum of 6 cycles.
Study NCT00980395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cladribine
Description: 4 mg/m2 IV over 2 hours Days 1-5. Repeat every 28 days for a maximum of 6 cycles.
Study NCT04916730 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Participants in this arm will receive nutritional counseling from the study dietician but will not be required to adopt a 10-hr eating window.
Study NCT04916730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Eating
Description: Participants in this arm will adhere to a daily, consistent self-selected 10-hr eating window for the course of the study intervention period as well as receive nutritional counseling from the study dietitian.
Study NCT02550496 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermoscopy
Study NCT03341988 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ombitasvir-Paritaprevir-Ritonavir Tab 12.5-75-50 milligram
Description: To asses curability of( Ombitasvir ,Paritaprevir,Ritonavir) in ch HCV infected patients in those with CKD vs ESRD 2- Also assess duration of sustained viral response,treatment, relapse or failure of therapy in CKD vs ESRD
Study NCT03088176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil
Description: Up to 4mL administered on C1D1 intratumorally
Study NCT03088176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparep 100 Mil Pfu/Ml 1Ml
Description: Up to 4 ML administered on Week 4 Day 1 and every 2 weeks thereafter
Study NCT03088176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: 150mg PO qday
Study NCT03088176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: 2mg PO qday
Study NCT02250196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-Asc
Description: received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
Study NCT01767025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Study NCT01767025 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sea water
Study NCT00614354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-glucarate solution
Description: Patients will receive a single 22 - 27 mCi bolus intravenous dose of 99mTc-glucarate solution, as soon as possible after their arrival in the emergency department or the chest pain center
Study NCT01843049 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Patients will receive from 5 to 6 weeks 5 days a week radiations. The dose of radiation will depend on the level they will be included.
Study NCT01843049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy (5-FU+DDP)
Description: Patients will receive 2 cycles of concurrent chemotherapy (cisplatin 25mg/m2 IV daily on Days 1-3 and 29-31 plus 5-FU 500mg/m2 IV continuous infusion over 24h daily on Days 1-4 and 29-32) during radiotherapy period. Consolidation chemotherapy (cisplatin 25mg/m2 IV daily on Days 1-3 plus 5-FU 600mg/m2 IV daily on Days 1-5, cycled every 4 weeks) will be given for 2 cycles one month after the end of radiochemotherapy.
Study NCT00838045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Bausch & Lomb Akreos TL IOL (MI60) posterior chamber IOL
Description: Surgery to implant the Bausch \& Lomb Akreos TL Intraocular Lens will be performed using standard microsurgical techniques following cataract surgery.
Study NCT04276649 — intervention group
Intervention type: DRUG
Intervention: Caltrate
Description: Patients in supplementary group were received with Caltrate 0.6 g/d and Mesalazine 4g/d orally at least 12 months, and those in non-supplementary only take Mesalazine 4g/d.
Study NCT01912599 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sensimed Triggerfish
Description: IOP will be measured with the Sensimed Triggerfish, which is a disposable silicone contact lens embedded with a wireless sensor. The sensing resistive gauge in the device is circular around the center of the lens and is placed over a circumference of 11.5 mm in diameter. This corresponds to the corneoscleral junction position, where maximum corneal deformation occurs as a result of changes in IOP. A soft patch containing the receiving antenna will be applied around the eye and transmits the information via wire to the recorder that the patient will wear around the waist. The patient can continue to wear spectacles during monitoring. The device records a total of 144 measurements over a 24-hour period.
Study NCT01912599 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Pressure
Description: Patients in both groups will be fitted with a blood pressure cuff that will measure pressures for 24 hours.
Study NCT02868086 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OCT B-scans
Study NCT02868086 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT angiography
Study NCT00648895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: nebivolol 10mg, 20mg, 40mg daily dosage, oral administration
Study NCT00648895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol ER (TM)
Description: Metoprolol ER 100mg, 200mg, 400mg, daily dosage, oral administration
Study NCT04463485 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed Clamping
Description: Umbilical cord clamping was delayed 60 seconds at the end of second stage of labor.
Study NCT04202263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline Topical
Description: Placement of minocycline cream 0%, 1%, 2% or 3% at one of four identical allergen skin test sites.
Study NCT04202263 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placement of minocycline cream 0%
Study NCT02199444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer
Description: The dose of Sev was 2400 mg (800 mg three times a day) in all patients.
Study NCT02199444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00795639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitaxsentan
Description: Sitaxsentan = 100 mg tablet administered orally, once daily
Study NCT03458650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXI-15028 50mg
Description: In escalated single-dose study, the subjects in each dose group will receive single oral dose of 50 mg LXI-15028 tablet or 1 matching placebo tablet at fasted state,
Study NCT03458650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXI-15028 100mg
Description: 100 mg LXI-15028 tablet or matching placebo 1 tablet at fasted state, In multiple-dose study, the subjects who administered 100mg single dose will continuously receive oral 100 mg LXI-15028 tablet or 1 matching placebo tablet once daily (QD) for 10 times.
Study NCT03458650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXI-15028 200mg
Description: single oral dose 2 100 mg LXI-15028 tablets or 2 matching placebo tablets at fasted state
Study NCT00795639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sitaxsentan Placebo = 1 tablet administered orally, once daily
Study NCT00407485 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ziv-aflibercept
Description: Given IV
Study NCT00407485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02297854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir Hydrochloride
Description: Valganciclovir Hydrochloride Tablets 450 mg
Study NCT02297854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir Hydrochloride
Description: Valganciclovir Hydrochloride Tablets 450 mg
Study NCT03122444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipramine
Description: Imipramine will be given daily for 21-30 days.
Study NCT01074996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: 40-60mg bid , days 1-14, every 3 weeks
Study NCT01074996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 plus Leucovorin
Description: S-1 40-60mg bid, days 1-14 , every 3 weeks Leucovorin 25mg bid , days 1-14 , every 3 weeks
Study NCT04631874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDFF0318, Champix
Description: CDFF0318: Varenicline salt changed Champix: Varenicline tartrate
Study NCT03781687 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral ESP Block
Description: Bilateral ESP Block will be performed at T8
Study NCT03458650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo tablets
Study NCT02346253 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Internal Radiation Therapy
Description: Undergo high-dose-rate brachytherapy
Study NCT02346253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Given PO
Study NCT02346253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Given IM or SC
Study NCT02346253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given SC
Study NCT02346253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin Pamoate
Description: Given IM
Study NCT02346253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Given SC
Study NCT02346253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02346253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00630344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Study NCT00630344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Study NCT01939327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide/Rituximab
Study NCT02774369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Individualized aerobic intervention program
Study NCT02774369 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral therapy
Description: Psychological intervention combining behavioral, cognitive, and educational strategies
Study NCT04240158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-6463
Description: IW-6463 Tablet
Study NCT04240158 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo Tablet
Study NCT00118742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil [CellCept]
Description: 1-1.5 g orally or intravenously twice daily
Study NCT00118742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil [CellCept]
Description: 1-1.5 g orally or intravenously twice daily
Study NCT00118742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: As prescribed, for 12 months
Study NCT00118742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: As prescribed, for 12 months
Study NCT00118742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: 2-4 mg orally once daily for 9-11 months
Study NCT02575170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amino acid solution
Description: a balanced mixture of 18 pure crystalline amino acids, eight of which are essential amino acids
Study NCT02575170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ringer's lactate solution
Description: 200 ml of Ringer's lactate solution
Study NCT04602442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXO 1 inhalation
Description: Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10\^10 of nanoparticles (exosomes) of the first type.
Study NCT04602442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXO 2 inhalation
Description: Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10\^10 of nanoparticles (exosomes) of the second type.
Study NCT04602442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inhalation
Description: Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes).
Study NCT03853863 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: in-school walking training with minimalist shoes
Description: Participants in the MSW group will be given a pair of minimalist shoes for all in-school activities (i.e., 5 days/week and 7 hours/day) for 12 weeks. Similar to previous minimalist footwear studies, the intervention duration will be gradually increased over the 12-week training. In brief, subjects will wear the minimalist shoes for 1 out of 5 school days at the first week; 2 days at the second week, and so on until fully use of the minimalist shoes at the fifth week.
Study NCT03853863 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: in-school walking training with protective shoes
Description: Participants in the TSW group will be given a pair of given a pair of protective shoes with arch support for all in-school activities (i.e., 5 days/week and 7 hours/day) for 12 weeks,while follow the same wearing pattern as the MSW group.
Study NCT01235234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF101
Description: orally q12h
Study NCT01235234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CF101
Description: orally q12h
Study NCT03406013 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written Information
Description: Receive written information on diet and exercise relevant to older men with prostate cancer
Study NCT03406013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Information
Description: Receive written information on diet and exercise relevant to older men with prostate cancer
Study NCT03406013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prescription
Description: Participants receive tailored exercise prescription and tailored diet recommendations
Study NCT03781687 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral ESP Block
Description: Unilateral ESP Block will be performed at T8 (right side)
Study NCT03781687 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Morphine patient controlled analgesia device
Description: 24 hour morphine consumption will be recorded
Study NCT02250196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPMC 2
Description: received one sachet of SPMC at 7 p.m the evening before colonoscopy and another sachet of SPMC at 5 hours before procedure
Study NCT04606979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1x1 Low Intensity Transcranial Direct Current Stimulation (tDCS)
Description: tDCS will be delivered through a pair of identical square rubber electrodes (size 35 cm2), placed in rectangular saline-soaked sponges. For the stimulation of M1, electrodes will be placed over C3 or C4 according to the 10-20 EEG system, matching with the M1 contralateral to the performing dominant hand. The reference electrode will be positioned on F1 or F2, ipsilateral to the dominant hand.~The current stimulation will be slowly ramped up from 0 mA to 2 mA in one minute. For the anodal tDCS condition, this intensity will be maintained for the duration of the SRT-task (approximately 20 minutes). This will result in a current density of 0,057 mA/cm2. For the sham tDCS condition - unbeknown to the subject - stimulation will be gradually decreased towards 0 mA immediately after the one-minute ramp-up. During the last block of the SRT-task, this gradual ramping-up and -down of the current stimulation will be repeated to optimize the process of blinding of participants.
Study NCT04606979 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 1x1 Low Intensity Transcranial Direct Current Stimulation (tDCS)
Description: tDCS will be delivered through a pair of identical square rubber electrodes (size 35 cm2), placed in rectangular saline-soaked sponges. For the stimulation of M1, electrodes will be placed over C3 or C4 according to the 10-20 EEG system, matching with the M1 contralateral to the performing dominant hand. The reference electrode will be positioned on F1 or F2, ipsilateral to the dominant hand.~The current stimulation will be slowly ramped up from 0 mA to 2 mA in one minute. For the anodal tDCS condition, this intensity will be maintained for the duration of the SRT-task (approximately 20 minutes). This will result in a current density of 0,057 mA/cm2. For the sham tDCS condition - unbeknown to the subject - stimulation will be gradually decreased towards 0 mA immediately after the one-minute ramp-up. During the last block of the SRT-task, this gradual ramping-up and -down of the current stimulation will be repeated to optimize the process of blinding of participants.
Study NCT01271868 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IB1001
Study NCT04097106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Synbiotic
Description: Synbiotic dietary supplement in capsule form
Study NCT00185588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vatalanib
Description: Vatalanib 250 mg PO Q12 hours x 7 days, 8th day forward 500 mg PO Q12 hours
Study NCT00185588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 850 mg/m2
Study NCT03552380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: RP2D will be determined with a 6 patient safety lead-in. Entinostat will continue until disease progression or prohibitive toxicity. Cycles 1-4 are 21 day cycles. Cycles 5 and subsequent are 28 day cycles.
Study NCT03552380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will continue until disease progression or prohibitive toxicity. Cycles 1-4 are 21 day cycles. Cycles 5 and subsequent are 28 day cycles.
Study NCT03552380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be administered in combination with entinostat and nivolumab for Cycles 1-4 only.
Study NCT03347825 — intervention group
Intervention type: PROCEDURE
Intervention: Robotic-assisted lobectomy using da Vinci Surgical System
Description: Robotic-assisted lobectomy
Study NCT03347825 — intervention group
Intervention type: PROCEDURE
Intervention: VATS (video assisted thoracic surgery)
Description: VATS (video assisted thoracic surgery)
Study NCT03347825 — intervention group
Intervention type: PROCEDURE
Intervention: Open lobectomy
Description: Open lobectomy
Study NCT03301545 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fast-Track to Bariatric Surgery
Description: 30 participants from the urban Indigenous community who have Type 2 diabetes and are candidates for bariatric surgery at the Centre for Metabolic and Bariatric Surgery will be randomized to the fast-track to bariatric surgery group.
Study NCT01861496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LiPlaCis
Description: LiPlaCis IV every 3 weeks on day 1, day 8
Study NCT04461899 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood test
Description: additional blood test will be done 3 and 12 months after endometrioma sclerotherapy.